Skip to main content
Fig. 1 | BMC Pharmacology and Toxicology

Fig. 1

From: Melatonin enhances everolimus efficacy in breast cancer by suppressing mTOR pathway activation and promoting apoptosis and mitochondrial function

Fig. 1

Melatonin and everolimus combined therapy decreases MCF-7 proliferation. (A) MCF-7 cells were treated over 24, 48, 72 h with melatonin (2, 4, 5, 6 mM), everolimus (7.81, 15.6, 31.25, 62.5, 125 nM), and cell viability was assessed. (B) Cell viability in MCF-7 cells was investigated by combining 4 mM and 2 mM melatonin with varying dosages of everolimus for 24, 48, and 72 h. Normalized results for cell viability assays were represented as a percentage of the control. The data come from three separate trials. (C) Cell scratch assays were performed at 0, 24, 48, and 72 h in the treatments containing the control, melatonin (3 mM), everolimus (30 nM), and the combination of melatonin and everolimus. DMSO serves as a negative control. The amount of gap closing caused by the cells was measured and displayed as bar graphs. (Three separate tests were conducted). The bars represent mean ± SEM. *p < 0.05, **p < 0.005, ***p < 0.0005

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us